Lilly's orforglipron consistent with injectable GLP-1 medicines in Phase 3 trial

Apr 18, 2025

According to an official statement from Eli Lilly and Company, "Orforglipron is the first oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist, taken without food...

Study discovers how higher doses of oral semaglutide improve blood sugar control, weight loss

Jun 30, 2023

Diabetes is a chronic condition that makes it difficult to regulate blood sugar levels. For many people, the condition worsens with time, making it...

CDSCO issues advisory to curb misleading promotion of prescription medications for obesity

Mar 11, 2026

The Central Drugs Standard Control Organization (CDSCO) has issued an advisory to pharmaceutical manufacturers, importers, and marketing authorization holders to ensure strict compliance with...

Govt issues guidelines on GLP-1 Drugs' use, risks, and regualtions

Apr 01, 2026

The Government of India on Thursday released details on the GLP -1 Drugs' use, risks, and regulation, according to an official press release.

GLP-1 should not be used as a quick fix for weight loss and diabetes management, warns top experts

Mar 30, 2026

Top medical experts are raising urgent alarms against using GLP-1 as a lifestyle enhancer, highlighting the risk of shortages for high-risk patients.

Drug regulator inspects 49 entities over unauthorised sale of weight loss drugs

Mar 24, 2026

India's drug regulator has intensified monitoring of the supply chain of GLP-1-based weight loss drugs amid concerns over their unauthorised sale and misuse.